Abbot Buys Kos For $3.7 Billion

Nov. 6, 2006
Adds cholesterol treatments to product line.

U.S. healthcare group Abbott Laboratories said Nov. 6 it was acquiring Kos Pharmaceuticals Inc. for $3.7 billion to add cholesterol treatments to its business. "Kos Pharmaceuticals is an excellent strategic fit for Abbott, both scientifically and commercially," Abbott chief executive Miles White said.

"This acquisition expands Abbott's presence in the lipid management market and will provide several on-market and late-stage pipeline products," he said.

Kos's two main drugs are Niaspan, a tablet that raises "good" levels of cholesterol, and another cholesterol treatment called Advicor. Such treatments are turning into blockbusters for drug companies as wealthier countries tackle rising levels of obesity.

Abbott is paying $78 per share for Kos, a hefty premium of 56% on the drugmaker's closing price on Nov. 3.

Copyright Agence France-Presse, 2006

Continue Reading

Popular Sponsored Recommendations

Lean Manufacturing in the Age of the Industrial Internet

Oct. 24, 2023
Read how advanced MES capabilities can help you improve your labor utilization, reduce WIP, and optimize your production. Download the white paper today.

Digitally Transforming Data and Processes With Product Lifecycle Management

Oct. 29, 2023
Manufacturers face increasing challenges in product development as they strive to consistently deliver improved results. Discover how industry leaders are improving time-to-market...

Gain a competitive edge with real-world lessons on private 5G networks

Nov. 16, 2023
The use of private networks in manufacturing applications is rapidly growing. In this paper, we present valuable insights and lessons learned from the field with the goal of enhancing...

You Cannot Stay Competitive by Bolting New Technologies to a Legacy ERP

Oct. 20, 2023
Read this white paper to understand the benefits of shifting to a next-generation ERP system as part of a DOP.

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!